by Phil Wolfson | Jan 10, 2023 | KRF Publications
Ketamine is a general anesthetic with over 50 years of safe administration that is in increasing use for psychiatric indications. This is evidenced by the recent FDA approval of intranasal esketamine (the S-enantiomer) for the treatment of depression. With...
by Phil Wolfson | Jan 10, 2023 | KRF Publications
Combat veterans are at high risk for the development of posttraumatic stress disorder (PTSD) and substance use disorders. Ketamine has been shown to be an effective treatment for numerous mental health disorders, although research on its efficacy in combat-related...
by Phil Wolfson | Jan 10, 2023 | KRF Publications
An invitation for the creation of justice, fairness and connection That I knew everyone in Will Hall’s collection/selection of admitted, convicted and accused perpetrators came as no surprise to me and Kylea Taylor’s response to the Center for...
by Phil Wolfson | Jan 10, 2023 | KRF Publications
Based on what may well be the most intensive psychotherapy with subjects who have trauma from life-threatening illnesses (LTI), with MDMA experiences as a fundamental part of the process, a new entity is defined—PTSD-LTI.The diverse phenomena of this trauma are...
by Phil Wolfson | Jan 10, 2023 | KRF Publications
Currently, ketamine is the only legal psychedelic medicine available to mental health providers for the treatment of emotional suffering. Over the past several years, ketamine has come into psychiatric use as an intervention for treatment resistant depression (TRD),...
